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Inhibition of thromboxane synthesis with OKY-046 might be useful for the prevention of ischemia-induced ventricular arrhythmias.
Since the release of thromboxane A2 (TXA2), which contracts the coronary artery and induces platelet aggregation, is thought to exert a deleterious influence on the regu lation of the coronary circulation, inhibition of TXA2 synthesis might therefore have a beneficial effect on myocardial ischemia (1, 2). However, there is little information con cerning the possible effects of TXA2 inhibition on cardiac arrhythmias in the ischemic setting. The present study was performed to assess the effects of a specific TXA2 synthetase inhibitor, OKY-046 (3), on ventricular arrhy thmias both during 30 min of coronary artery ligation and subsequent reperfusion and on coronary sinus prostaglandins in anesthetized dogs.
Nineteen mongrel dogs weighing from 1 5 to 20 kg were anesthetized with sodium pen tobarbital (30 mg/kg, intravenously) under artificial ventilation with a Harvard ventilator. Catheters were placed in the aorta, the coro nary sinus and the external jugular vein. Both aortic blood pressure and surface ECG were continuously monitored. Following a mid sternal thoracotomy, the heart was suspended in a pericardial cradle and a ligature placed around the left anterior descending artery just proximal to the first diagonal branch. K+ sensitive electrodes made from a valinomycin polyvinyl chloride matrix membrane were inserted to the center of the expected ischemic myocardium, and the interstitial K+ concen trations ([K+]) were monitored (4, 5). In nine dogs (OKY group), a bolus of 5.0 mg/kg of OKY-046 (Ono Pharmaceutical Co., Ltd., Osaka, Japan) was dissolved in saline and injected intravenously followed by intra venous drip infusion at 2.0 mg/kg/hr 30 min prior to the coronary ligation. Ten control dogs (control group) received appropriate volumes of saline. The coronary artery was ligated and released 30 min later, resulting in reperfusion of the formerly ischemic myocar dium. Blood samples were taken from the coronary sinus before ligation, just before reperfusion and immediately after reperfusion. Thromboxane B2 (TXB2) and 6-keto pro staglandin F1a (6-keto PGF1a), i.e., stable degradation products of TXA2 and prosta glandin 12 (PG12), respectively, were measured by a specific radioimmunoassay.
All data were expressed as the mean±S.E.M. Statistical significance between the control and the OKY group was determined using the un paired Student's t-test. Differences were considered significant when P<0.05.
The number of ventricular premature con tractions (VPC) during coronary ligation and the incidence of ventricular fibrillation (VF) within 30 min after reperfusion in the control and the OKY group are shown in Fig. 1 . In the control group, the mean number of VPC during ligation was 266±91, and the inci dence of VF after reperfusion was 70%, while both the mean number of VPC during ligation (30±21) and the incidence of VF after reperfusion (22%) in the OKY group were significantly lower than those in the control group (P<0.05).
The changes in coronary sinus TXB2 and 6-keto-PGF1a concentrations before and during coronary ligation and after reperfusion in the both groups are shown in Fig. 2 . Before ligation, TXB2 concentration (631 ±252 pg/ml) and 6-keto PGF1a concen tration (731 ±135 pg/ml) in the OKY group were lower than those in the control group (860±222 pg/ml and 733±149 pg/ml, re spectively), but they were not statistically significant. OKY significantly reduced TXB2 concentrations both during ligation (1040 ±232 pg/ml vs. 317±64 pg/ml, P<0.01) and after reperfusion (953±242 pg/ml vs. 389±77 pg/ml, P<0.05) as compared to the control group, while there were no significant differences in 6-keto-PGF1a concentrations between the control and the OKY group both during ligation (1051 ±298 pg/ml vs. 666± 121 pg/ml) and after reperfusion (1183±408 pg/ml vs. 814±158 pg/ml). Furthermore, the TXB2/6-keto-PGF1a ratio, which indicates the balance between these two substances, was lower in the OKY group (<1.0) than that in the control group (>1.0) both during ligation and after reperfusion. [K+] measured by K+-sensitive electrodes before ligation was 3.8±0.2 mM in the control group and 3.6±0.2 mM in the OKY group, this being not statis tically significant. [K+] was rapidly elevated just after coronary ligation in both groups. However, the maximal concentration in the OKY group (8.6±0.5 mM) was significantly lower than that in the control group (13.6±1.3 mM, P<0.01).
Prior to the administration of OKY-046, there were no significant differ ences in mean blood pressure and heart rate between the control (98±9 mmHg and 166±7/min, respectively) and the OKY group (96±7 mmHg and 156±19/min). Mean blood pressure was slightly decreased after the administration of OKY-046 (81 ±6 mmHg), but it was not statistically significant. After the administration of OKY-046, there were no chances in PQ. QRS and QT intervals. The present study showed that inhibition of TXA2 synthesis with OKY-046 effectively prevents ventricular arrhythmias both during coronary artery ligation and after reperfusion. Fig. 2 . The effects of OKY-046 on plasma concentrations of thromboxane B2 (TXB2) (A) and 6-keto prostaglandin F,a (6-keto-PGF,a) (B) in the coronary sinus and TXB2/6-keto-PGF,a ratio (C) before and during coronary artery ligation and after coronary reperfusion.
Each value represents the meant S.E.M. *P<0.05, **P<0.01 compared to the control group.
The most likely explanation of the anti arrhythmic effects of OKY-046 involves its effects on the coronary microcirculation. With inhibition of TXA2 synthesis, arachidonic acid metabolism may be shunted toward PGI2 synthesis. Since TXA2 contracts the coronary artery and induces platelet aggregation, whereas PG 12 has opposite effects, either reduction of TXA2 concentration or increase of PGI2 concentration in the coronary circulation is thought to protect the ischemic myocardium (6). In the OKY group, since TXB2 concentration in the coronary sinus was significantly reduced, the TXB2/6-keto-PGF1a ratio was lower than 1.0, in contrast to the control group. It is possible that inhibition of TXA2 synthesis and the improvement of the TXA2/PGI2 balance with OKY-046 reduce the severity of myocardial ischemia, resulting in a prevention of ventricular arrhythmias during coronary ligation. This protective effect, which is also shown by the fact that OKY-046 sig nificantly reduced the increased [K+] after coronary ligation, a reliable parameter of the ischemic state, corresponds to the reports that OKY-046 significantly reduced lactate pro duction during myocardial ischemia (2) and the infarct volume after five hours of coronary artery ligation (7). With sudden reperfusion, the rapid onset of the electrical instability seen within seconds strongly suggests a process dependent on a washout or redis tribution of metabolites stored in the ischemic myocardium (8). Therefore, the antiarrhythmic effects of OKY-046 seen after reperfusion might reflect a reduction of the metabolites such as TXA2 or K+: Washout of TXA2 might exacerbate ischemic changes by platelet ag gregation and vasoconstriction in the perfused myocardium, and washout of K+ might cause the electrical gradients resulting in the elec trical inhomogeneity across the ischemic myocardium.
Whether the antiarrhythmic effects of OKY 046 simply reflect a reduction of the severity of the myocardial ischemia remains to be elucidated: There might be a direct electro physiological effect of TXA2 inhibition. Ac cording to the recent report that a stable TXA2 analog does not directly influence either action potential parameters or activation patterns both in the infarcted and non infarcted myocardium in dogs (9), the expected electrophysiological effect of TXA2 inhibition might be caused by a relative increase in PG12 concentration and resulting improvement of the TXA2/PG12 balance. Further studies are needed to delineate the electrophysiological effects of prostaglandins and its synthetase inhibitors in the ischemic setting.
